Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR3 | P49019 | 3/20 | 0.66 |
| ▸ | MAPT | P10636 | 7/20 | 0.60 |
| ▸ | POLB | P06746 | 2/20 | 0.60 |
| ▸ | PKM | P14618 | 2/20 | 0.60 |
| ▸ | KAT2B | Q92831 | 3/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | PRSS1 | P07477 | 4/20 | 0.51 |
| ▸ | BCHE | P06276 | 1/20 | 0.50 |
| ▸ | ACHE | P22303 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | CRHBP | P24387 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4086159 | 0.90 | HCAR3 (0.63) | HCAR3MAPTPOLBPKMKAT2B | |
| SCHEMBL1420938 | 0.85 | HCAR3 (0.58) | HCAR3MAPTPOLBPKMKAT2B | |
| SCHEMBL8336041 | 0.84 | ALDH1A1 (0.56) | HCAR3MAPTPOLBPKMKAT2B | |
| SCHEMBL14906561 | 0.84 | KAT2B (0.74) | HCAR3MAPTPOLBPKMKAT2B | |
| SCHEMBL1283854 | 0.84 | MAPT (0.54) | HCAR3MAPTPOLBPKMKAT2B | |
| SCHEMBL29306545 | 0.84 | HCAR3 (0.67) | HCAR3MAPTPOLBPKMKAT2B | |
| SCHEMBL4090213 | 0.83 | HCAR3 (0.61) | HCAR3MAPTPOLBPKMKAT2B | |
| SCHEMBL10428098 | 0.83 | HCAR3 (0.66) | HCAR3MAPTPOLBPKMKAT2B | |
| SCHEMBL20968369 | 0.83 | HCAR3 (0.66) | HCAR3MAPTPOLBPKMKAT2B | |
| SCHEMBL19972855 | 0.83 | HCAR3 (0.66) | HCAR3MAPTPOLBPKMKAT2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2319512-A1 | Novel 2-amino benzimidazole derivatives and their use as modulators of small-conductance calcium-activated potassium channels. | NeuroSearch AS (DK) | 2011-05-11 | — | — | EP | disclosed |
| US-20110034527-A1 | NOVEL 2-AMINO BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS MODULATORS OF SMALL-CONDUCTANCE CALCIUM-ACTIVATED POTASSIUM CHANNELS | SOERENSEN ULRIK SVANE | 2011-02-10 | — | — | US | disclosed |
| US-7842817-B2 | 2-amino benzimidazole derivatives and their use as modulators of small-conductance calcium-activated potassium channels | NEUROSEARCH A/S (DK) | 2010-11-30 | — | — | US | disclosed |
| EP-1838306-B1 | NOVEL 2-AMINO BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS MODULATORS OF SMALL-CONDUCTANCE CALCIUM-ACTIVATED POTASSIUM CHANNELS | NEUROSEARCH AS (DK) | 2010-11-17 | — | — | EP | disclosed |
| US-20100280087-A1 | NOVEL 2-AMINO BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS MODULATORS OF SMALL-CONDUCTANCE CALCIUM-ACTIVATED POTASSIUM CHANNELS | SOERENSEN ULRIK SVANE | 2010-11-04 | — | — | US | disclosed |
| US-20080200529-A1 | Novel 2-Amino Benzimidazole Derivatives and Their Use As Modulators Of Small-Conductance Calcium-Activated Potassium Channels | NEURO SEARCH A/S (DK) | 2008-08-21 | — | — | US | disclosed |
| EP-1838306-A1 | NOVEL 2-AMINO BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS MODULATORS OF SMALL-CONDUCTANCE CALCIUM-ACTIVATED POTASSIUM CHANNELS | NEUROSEARCH A/S (DK) | 2007-10-03 | — | — | EP | disclosed |
| WO-2006074991-A1 | NOVEL 2-AMINO BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS MODULATORS OF SMALL-CONDUCTANCE CALCIUM-ACTIVATED POTASSIUM CHANNELS | NEUROSEARCH A/S (DK) | 2006-07-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110034527-A1 | NOVEL 2-AMINO BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS MODULATORS OF SMALL-CONDUCTANCE CALCIUM-ACTIVATED POTASSIUM CHANNELS | KCNN2, KCNN1, KCNN3 | HCAR3 974/4885MAPT 1733/4885POLB 4729/4885 |
| US-20080200529-A1 | Novel 2-Amino Benzimidazole Derivatives and Their Use As Modulators Of Small-Conductance Calcium-Activated Potassium Channels | KCNN2, KCNN1, KCNN3 | HCAR3 974/4885MAPT 1733/4885POLB 4729/4885 |
| US-20100280087-A1 | NOVEL 2-AMINO BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS MODULATORS OF SMALL-CONDUCTANCE CALCIUM-ACTIVATED POTASSIUM CHANNELS | KCNN2, KCNN1, KCNN3 | HCAR3 974/4885MAPT 1733/4885POLB 4729/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.